Form 4: DexCom EVP Teri L Lawver Reports Acquisition of 26,053 Shares of Common Stock

Teri L Lawver, EVP and Chief Commercial Officer of DexCom Inc., reports acquiring 26,053 shares of common stock through a grant of restricted stock units.

Summary

• On March 8, 2024, Teri L Lawver, EVP and Chief Commercial Officer of DexCom Inc., acquired 26,053 shares of DexCom's common stock.
• The acquisition was a grant of restricted stock units (RSUs) at a price of $0.0.
• These RSUs vest in three equal annual installments from the date of grant.
• Following the transaction, Lawver beneficially owns 71,405 shares of DexCom common stock, including 60,067 unvested restricted stock units.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices and aligns executive interests with the company's performance.

Positives

• The grant of restricted stock units aligns the executive's interests with the long-term performance of the company.
• The vesting schedule encourages continued service and commitment from the executive.

Industry Context

Executive compensation through stock grants is a common practice in the industry to incentivize performance and align executive interests with shareholder value.

Comparison to Industry Standards

• Stock grants are a typical component of executive compensation packages in the technology and healthcare industries.
• Companies like Medtronic and Abbott also utilize stock options and restricted stock units to incentivize their executives.

Stakeholder Impact

• The stock grant could have a slightly positive impact on shareholder sentiment as it aligns executive interests with shareholder value.

Key Dates